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Abstract
With over eight million cases of tuberculosis each year there is a pressing need for the development of new vaccines against
Mycobacterium tuberculosis. Subunit vaccines consisting of recombinant proteins are an attractive vaccine approach due to
their inherent safety compared to attenuated live vaccines and the uniformity of manufacture. Addition of properly
formulated TLR agonist-containing adjuvants to recombinant protein vaccines enhances the antigen-specific CD4+ T cell
response characterized by IFN-c and TNF, both of which are critical for the control of TB. We have developed a clinical stage
vaccine candidate consisting of a recombinant fusion protein ID93 adjuvanted with the TLR4 agonist GLA-SE. Here we
examine whether ID93+GLA-SE can be improved by the addition of a second TLR agonist. Addition of CpG containing DNA
to ID93+GLA-SE enhanced the magnitude of the multi-functional TH1 response against ID93 characterized by co-production
of IFN-c, TNF, and IL-2. Addition of CpG also improved the protective efficacy of ID93+GLA-SE. Finally we demonstrate that
this adjuvant synergy between GLA and CpG is independent of TRIF signaling, whereas TRIF is necessary for the adjuvant
activity of GLA-SE in the absence of CpG.
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Introduction
Approximately two billion people are infected with Mycobacte-
rium tuberculosis (M.tb.) the causative agent of tuberculosis (TB). In
2011 there were over 8 million cases of active TB leading to 1.5
million deaths worldwide. The only vaccine against TB, BCG
limits childhood disease, but is variably effective against pulmo-
nary TB in adults, with efficacy estimates ranging from 0 to 80%
[1]. Thus there is a pressing need for new vaccine candidates
against this devastating disease. In the last decade there has been
considerable effort to develop new candidate vaccines against TB,
with several entering clinical testing [2].
M.tb. is primarily controlled by TH1 cells producing IFN-c and
TNF that activate infected macrophages, as well as IL-2 which
sustains the T cell response [3]. This has led to the hypothesis that
the magnitude of the multifunctional TH1 cells (i.e. cells producing
IFN-c, TNF, and IL-2) is important for an effective vaccine
response against M.tb. [4]. Thus enhancing the magnitude of the
TH1 response against candidate vaccine antigens is critical for
developing an effective vaccine against TB. We have developed a
clinical candidate antigen, ID93, which is a fusion of four M.tb.
proteins: Rv1813, Rv2608, Rv3619, and Rv3620. When paired
with the adjuvant GLA-SE, prophylactic immunization with
ID93+GLA-SE limits M.tb. in mice and guinea pigs [5].
Therapeutic vaccination with ID93+GLA-SE is an effective
adjunct to chemotherapy in M.tb. infected mice and non-human
primates [6]. The adjuvant GLA-SE contains the synthetic TLR4
agonist GLA formulated in a stable oil-in-water nano-emulsion
(SE) [7,8]. In the absence of GLA, ID93 formulated in SE elicits a
weak, non-protective TH2 response in mice. Therefore inclusion of
a TLR4 agonist is essential for the efficacy of this vaccine [9].
Additionally the nature of the vaccine formulation can have
profound effects on both the immunogenicity and efficacy of
ID93+GLA vaccines[10]. ID93+GLA-SE is currently undergoing
Phase I clinical testing [11].
Although TLR4 agonists such as GLA and monophosporyl lipid
(MPLA) are the most clinically advanced TLR agonist adjuvants
for vaccines, with MPLA included in several licensed vaccines,
other TLR agonists are also being developed as vaccine adjuvants
[12–15]. Additionally there is substantial interest in combining
TLR agonists as vaccine adjuvants to enhance immunogenicity
and efficacy. In vitro and in vivo studies have found that certain
combinations of TLR agonists can cooperate to enhance cytokine
and chemokine production by professional antigen presenting cells
such as dendritic cells and macrophages, whereas other combina-
tions of agonists can impair vaccine efficacy [16–18]. Several
groups have found that combining two or three TLR agonists can
enhance T cell and antibody responses against experimental
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vaccines [17,19–21]. In our own work we have shown that
combining MPLA or GLA with a TLR9 agonist CpG enhances
the efficacy of a candidate therapeutic vaccine against Leishmaniasis
[22].
The different TLRs signal either through MyD88 (TLR2,
TLR5, TLR7, TLR8 and TLR9), TRIF (TLR3) or both signaling
pathways (TLR4) [23]. Effective enhancement of adjuvant activity
with multiple TLR agonists is most often seen with combinations
of agonists that activate the TRIF pathway with agonists that
activate the MyD88 pathway. This has led to the hypothesis that
MyD88 and TRIF cooperation is necessary for enhanced adjuvant
activity with a combination of TLR agonists [16,17,24]. We
present evidence that combining TLR4 and TLR9 agonists
enhances the TH1 response against ID93 and leads to increased
protection against aerosolized M.tb. challenge. Further we explore
the contribution of TRIF to this enhanced immunogenicity.
Materials and Methods
Ethics statement
The study was conducted under protocol number 2011/5
approved by the Infectious Disease Research Institute Institutional
Animal Care and Use Committee.
Animals and immunizations
6–8 week old female C57BL/6 mice were purchased from
Charles River and The Jackson Laboratory and maintained in
Specific Pathogen Free conditions. TRIF2/2 (also known as
Ticam12/2) breeder mice on the C57BL/6 background were
purchased from The Jackson Laboratory and bred in-house. After
infection animals were maintained in ABSL3 containment. Mice
were immunized three times three weeks apart by intramuscular
injection. Each immunization contained 0.5 mg of ID93 recom-
binant protein [5] with 5 mg of GLA (Avanti Polar Lipids), 8 mg of
CpG1826 (Oligos, Etc.), or both. Adjuvants were formulated in-
house in IDRI’s stable emulsion (SE), as described previously [8].
For BCG immunization 56104 CFU (Pasteur strain, Sanofi
Pasteur) were injected intradermally once at the time of the first
subunit immunization.
Intracellular cytokine staining
One week after the final immunization splenocytes were isolated
from three to five animals per group. Red blood cells were lysed
using Red Blood Cell Lysis Buffer (eBioscience) and resuspended
in RPMI 1640 and 10% FBS. Cells were plated at 26106 cells/
well in 96-well plates and were stimulated for 1 hour with media
or ID93 (10 mg/mL) at 37uC. GolgiPlug (BD Biosciences) was
added and the cells were incubated for an additional 7 hours at
37uC. Cells were washed and surface stained with fluorochrome
labeled antibodies to CD4 (clone GK1.5), CD8 (clone 53–6. 7),
and CD44 (clone IM7) (BioLegend and eBioscience) in the
presence of 20% normal mouse serum for 20 minutes at 4uC. Cells
were washed and permeabilized with Cytofix/Cytoperm (BD
Biosciences) for 20 minutes at room temperature. Cells were
washed twice with Perm/Wash (BD Biosciences) and stained
intracellularly with fluorochrome labeled antibodies to IFN-c
(clone XMG-1.2), IL-2 (JES6-5H4), TNF (MP6-XT22) (BioLe-
gend and eBioscience), IL-5 (clone TRFK5), and IL-17 (clone
TC11-18H10.1) for 20 minutes at room temperature. Cells were
washed and resuspended in PBS. Up to 106 events were collected
on a four laser LSRII Fortessa flow cytometer (BD Biosciences).
Data were analyzed with FlowJo. Cells were gated as singlets .
lymphocytes . CD4+ CD82 . CD44+ . cytokine positive.
Analysis and presentation of distributions was performed using
SPICE version 5.2, downloaded from ,http://exon.niaid.nih.
gov/spice.
MHC class II tetramer production and staining
ID93-specific I-Ab tetramers with the immunodominant epitope
from Rv3619 (VIYEQANAHGQ) and Rv2608 (AVLPPEVNSA)
were produced using methods previously described [25,26]. One
week after the final immunization splenocytes were isolated as
described above. Cells were then stained for one hour at room
temperature with 10 mM tetramer. Cells were washed and stained
for surface CD4, CD8, and CD44. Up to 106 events were collected
on a four laser LSRFortessa flow cytometer (BD Biosciences). Cells
were gated as singlets. lymphocytes. CD82 CD4+. CD44+.
tetramer+.
Mtb aerosol challenge and enumeration
Four to twelve weeks after the last immunization, mice (n = 7/
group) were aerogenically infected with M. tuberculosis H37Rv
(ATCC No. 35718; American Type Culture Collection) using a
GlasCol aerosol generator calibrated to deliver 50–100 bacteria
into the lungs. To confirm the amount of bacteria delivered an
additional three unimmunized animals per infection were eutha-
nized one day later and bacterial burden in the lungs were
enumerated. Protection was determined three to four weeks after
challenge by harvesting the lungs from the infected mice,
homogenizing the tissue in 0.1% PBS–Tween 80, and plating 5-
fold serial dilutions on7H10 agar plates (Molecular Toxicology) for
bacterial growth. Bacterial colonies were counted after incubation
at 37uC with 5% CO2 for 14–21 days.
Histology
Formalin-fixed lung lobes were embedded in paraffin, sectioned
and stained with hematoxylin and eosin as a purchased service by
the Benaroya Research Institute Histology Core (Seattle, WA).
Images were obtained at 106 magnification using a Nikon DS
Camera Control Unit DS-L2 on a Nikon Eclipse E400 compound
microscope.
Cytokine production by macrophages
Single cell suspensions of mouse splenocytes were stimulated
with media, GLA (1 mg/mL), CpG (10 mg/mL), or both in the
presences of Brefeldin A for eight hours using a method adopted
from Hajjar et al. [27]. Cells were washed with PBS and treated
with anti-CD16/CD32 blocking antibody (clone 93). Cells were
washed and surface stained with fluorochrome labeled antibodies
to CD3 (clone 17A2), CD19 (clone 1D3), CD11b (clone m1/70),
and Ly6G (clone 1A8) (BioLegend and eBioscience) for 20 minutes
at 4uC. Cells were washed and permeabilized with Cytofix/
Cytoperm (BD Biosciences) for 20 minutes at room temperature.
Cells were washed twice with Perm/Wash (BD Biosciences) and
stained intracellularly with fluorochrome labeled antibodies to IL-
12p40 (clone C17.8), TNF, and IL-6 (clone MP5-20F3) (BioLe-
gend and eBioscience) for 20 minutes at room temperature. Cells
were washed and resuspended in PBS. Up to 106 events were
collected on a four laser LSRII Fortessa flow cytometer (BD
Biosciences). Data were analyzed with FlowJo. Cells were gated as
singlets . CD32CD192 . not neutrophils (Ly6Ghi CD11bhi) .
macrophages (CD11b+) . cytokine positive.
Statistical methods
Bacterial burdens were normalized by log10 transformation.
Statistical significance of differences in bacterial burden and
cytokine production were determined by analysis of variance using
Adjuvant Synergy for TB Vaccines
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the Bonferroni correction for multiple comparisons using Prism 5
(GraphPad Software).
Results
Enhanced TH1 responses to ID93 with the combination
adjuvant GLA and CpG
To determine whether a combined CpG and GLA adjuvant
would enhance the CD4+ T cell response to ID93 we immunized
C57BL/6 mice with ID93 adjuvanted with GLA, CpG, or both.
All vaccines were formulated as stable nanodroplet emulsions (SE)
[8]. One week after the third immunization we determined the
frequency of CD4+ T cells specific for two immunodominant
epitopes of ID93 by MHC class II tetramer staining. ID93+CpG-
SE elicited greater frequencies of ID93-specific CD4+ T cells
compared to ID93+GLA-SE (Figure 1A and B). Combining the
two TLR agonists further enhanced the frequency of ID93-specific
CD4+ T cells. When splenocytes were stimulated with ID93 and
assessed for cytokine production we found that ID93+GLA-SE
and ID93+CpG-SE elicited similar frequencies of CD4+ T cells
producing IFN-c, TNF, or IL-2 (Figure 1C). We did not detect
appreciable levels of IL-17 or IL-5 producing cells from these
immunizations (data not shown). Combining GLA and CpG more
than doubled the frequency of cytokine producing CD4+ T cells
(Figure 1C). To determine the extent of multi-functionality of these
ID93 specific cells we analyzed the frequency of cells making all
combinations of IFN-c, TNF, and IL-2. The overall distribution of
cells was similar across all three immunization regimens, with
ID93+CpG/GLA-SE eliciting more cells in all categories
(Figure 1D). The vast majority of ID93-specific CD4+ T cells
produced both IFN-c and TNF with approximately half of these
cells also producing IL-2. Taken together these data demonstrate
that the combination adjuvant CpG/GLA-SE augments produc-
tion of multi-functional TH1 cells to a greater extent than either
GLA-SE or CpG-SE.
GLA and CpG cooperate to enhance the protective
efficacy of ID93
Although IFN-c and TNF are critical for control of M.tb., there
are conflicting reports regarding the correlation between the
magnitude of IFN-c and TNF producing T cells elicited by
vaccination and the degree of protective efficacy [3,28–30]. To
determine whether the enhanced TH1 response generated by
ID93+CpG/GLA-SE resulted in more substantial protection
against M.tb. we challenged immunized mice with a low dose of
aerosolized M.tb. one month after the final immunization.
ID93+GLA-SE and ID93+CpG-SE immunization both conferred
substantial protection against M.tb. challenge (P,0.001 and
Figure 1. GLA and CpG combine to enhance TH1 responses to ID93. Mice were immunized with ID93 adjuvanted with GLA, CpG, or
GLA+CpG. (A and B) One week after the final immunization ID93-specific CD4+ T cells were identified by staining with I-Ab tetramers presenting
dominant epitopes from Rv2608 and Rv3619. Cells are gated as singlet, CD4+ CD44+. Splenic ID93-specific TH1 CD4
+ T cells from immunized mice
were identified by cytokine production following ex-vivo restimulation with ID93 and analyzed for (C) total cytokine response or (D) poly-functional
responses. See Figure S1 for representative cytokine staining. Data are representative of four experiments with similar results with 3–5 animals per
group. *,**,***, and **** indicate P,0.05, 0.01, 0.001, and 0.0001 respectively, relative to GLA+CpG as determined by ANOVA using the Bonferroni
correction for multiple comparisons.
doi:10.1371/journal.pone.0083884.g001
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P,0.0001 relative to unimmunized, respectively) (Figure 2A).
Combining the two immunostimulants into the same adjuvant
formulation further reduced the M.tb. burden in the lungs of
infected mice to a level induced by BCG immunization
(Figure 2A). To determine whether this enhanced protective
response was long lasting we challenged a second cohort of
immunized mice three months after the final immunization. Again
we found that ID93+GLA-SE and ID93+CpG-SE both limited
the M.tb. burden in the lungs (Figure 2B). The combination
adjuvant further reduced the bacterial burden at this late time
point, indicating that this superior protective efficacy was durable
and significant.
We also assessed cellular infiltration and lung pathology in the
animals challenged four weeks after immunization. In unimmu-
nized animals there was a significant reduction in free airway
space and substantial numbers of loosely aggregated granuloma-
tous structures (Figure S2). Immunization with ID93+GLA-SE or
ID93+CpG-SE resulted in greater free airway space, and fewer
areas of consolidated granulomas, however the granulomas that
developed were more structured than those seen in the unimmu-
nized animals. Immunization with ID93+CpG/GLA-SE extended
this protective benefit, with little sign of consolidated areas in the
lungs (Figure S2). Overall these data indicate that the enhanced
TH1 response elicited with the combined CpG/GLA-SE adjuvant
with ID93 correlated with enhanced protection both in terms of
reduced bacterial burden and limited lung pathology.
TRIF is not necessary for enhanced immunogenicity with
the combined GLA and CpG adjuvant
Both MyD88 and TRIF are necessary for the adjuvant activity
of GLA-SE [31]. To determine whether TRIF signaling is
necessary for GLA to augment the adjuvant activity of CpG-
SE we compared the cytokine production by C57BL/6 and
TRIF-deficient splenic macrophages stimulated with GLA, CpG,
or both. In the absence of TRIF, GLA induction of IL-6, IL-12p40
and TNF was substantially impaired, whereas there was little
impact on cytokine induction by CpG in the absence of TRIF
(Figure 3A). The combination of GLA and CpG enhanced
production of these cytokines in C57BL/6 macrophages and
surprisingly this additive effect was also present in TRIF-deficient
macrophages, indicating that TRIF may not be necessary for
enhanced adjuvant activity of the GLA and CpG combination.
To directly evaluate the contribution of TRIF signaling to the
enhanced adjuvant activity of GLA and CpG we immunized B6
and TRIF-deficient mice with ID93 adjuvanted with GLA-SE,
CpG-SE, or CpG/GLA-SE. As we saw previously (Figure 1) the
combination of GLA and CpG enhanced the frequency of CD4+
T cells producing IFN-c, TNF, and IL-2 upon restimulation with
ID93 (Figure 3B and C). In the absence of TRIF, ID93+GLA-SE
did not elicit ID93-specific TH1 cells. In TRIF-deficient mice the
magnitude of the TH1 response elicited by the combination GLA
and CpG adjuvant was substantially greater than that elicited by
CpG alone (Figure 3B and C). Thus GLA and CpG cooperate to
enhance the magnitude of the TH1 response to immunization in a
TRIF-independent fashion.
Discussion
TB remains one of the most clinically important infectious
diseases globally. By examining the breadth of T cell responses to
M.tb. proteins found in infected patients and evaluating the
potential for protection when delivered as a prophylactic vaccine
we have identified a set of candidate antigens for inclusion in new
subunit vaccine against TB. These antigens were initially identified
as protective in animal models when they were paired with a CpG
containing adjuvant [32]. We have found that these proteins are
also protective when delivered with the TLR4 agonist adjuvant
Figure 2. GLA and CpG combine to enhance the protective efficacy of ID93. Mice were immunized and challenged with a low dose of
aerosolized M.tb. (A) four or (B) twelve weeks later. M.tb. burdens in the lungs were determined four weeks after infection. Statistically significant
differences between vaccinated groups were determined by ANOVA using the Bonferroni correction for multiple comparisons. Data are
representative of three experiments with similar results with seven animals per group.
doi:10.1371/journal.pone.0083884.g002
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GLA-SE [5]. We now demonstrate that by combining CpG and
GLA in the same adjuvant formulation we can further enhance the
immunogenicity and protective efficacy of the ID93 vaccine
antigen. Further we find that although GLA signaling via the
TRIF pathway downstream of TLR4 is necessary for the adjuvant
activity of GLA-SE, TRIF is dispensable for the cooperative
benefit of combining GLA and CpG.
Infections are first recognized by pattern recognition receptors
(PRR) expressed by many cell types including professional APCs
such as macrophages and dendritic cells, which prime T cell
responses. PRR including TLR, RIG-I like receptors (RLR), C-
type lectin receptors (CLR) and NOD-like receptors (NLR)
recognize a diverse array of pathogen associated molecular
patterns (PAMP). PRR engagement leads to professional APC
maturation, increased antigen presentation and secretion of
cytokines and chemokines that direct the magnitude and quality
of the adaptive immune response [13]. Synthetic and naturally
derived PRR agonists have been widely used to mimic infection
and shape the immune response to recombinant proteins that
would otherwise be poorly immunogenic or tolerogenic [33].
Many infections are detected by multiple PRRs, allowing the
immune system to tailor the innate and adaptive immune response
to the particular pathogen [34]. For example, M.tb. is recognized
by TLR2 (MDP), TLR9 (CpG DNA), Mincle (trehalose
dimycolate) and NOD2 (MDP) [35].
Many studies have shown that triggering multiple PRR in vitro
can result in additive, synergistic, or antagonist effects on APC
maturation and secretion of cytokines including IL-12, IL-6, and
TNF [16,23,24,36–41]. This is true both of triggering multiple
receptors in the same class, such as multiple TLR agonists, as well
as across classes, such as TLR agonists combined with CLR or
NLR agonists [42,43]. Many live and inactivated vaccines
including BCG, Typhim, Influvac, and YF-17D engage multiple
PRR, which contributes to their immunogenicity and protective
efficacy [34,44]. Seminal work by Napolitani et al. demonstrated
that conditioning APCs with multiple TLR agonists enhanced
their ability to prime TH1 responses in vitro [16]. Enhanced activity
may arise from activation of additional APC types based on
receptor expression patterns, augmentation of APC cytokine
secretion, or synergistic signaling events in APCs downstream of
the different receptors [23]. For example, TLR4 signals through
both MyD88 and TRIF, whereas TLR7, 8 and 9 only signal
through MyD88. Based on the results of pairwise TLR agonist
combinations it has been proposed that signaling through both
MyD88 and TRIF were necessary for increased cytokine
production and T cell priming [16,18]. Indeed in the absence of
either TRIF or MyD88, synergistic production of cytokines by
dendritic cells stimulated with polyI:C and either MALP-2 or CpG
was abolished [17]. MyD88 was necessary for the increased CD8+
T cell response seen with peptide immunization adjuvanted with
MALP-2 and polyI:C [17]. In vitro activation of dendritic cells with
combinations of TLR3 and TLR9, TLR4 and TLR7, or TLR2
and TLR3 agonists enhanced their ability to induce CD8+ T cell
responses when transferred in vivo [17,38,40]. Despite the
plethora of data showing the efficacy of single PRR agonists as
vaccine adjuvants, there is surprisingly little data assessing the
Figure 3. Enhanced TH1 responses to GLA and CpG are independent of TRIF signaling. (A) C57BL/6 and TRIF
2/2 splenocytes were
stimulated ex vivo with GLA, CpG or both and analyzed for IL-6, IL-12p40, and TNF production by macrophages. (B and C) C57BL/6 and TRIF2/2 mice
were immunized with ID93 adjuvanted with GLA, CpG or GLA+CpG. Splenic ID93-specific TH1 CD+4 T cells from immunized mice were identified by
cytokine production following ex-vivo restimulation with ID93. Data are representative of two experiments with similar results with 3–5 animals per
group. *,**,***, and **** indicate P,0.05, 0.01, 0.001, and 0.0001 respectively, relative to GLA+CpG as determined by ANOVA using the Bonferroni
correction for multiple comparisons.
doi:10.1371/journal.pone.0083884.g003
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effects of combining PRR agonists for in vivo immunization. We
have shown that combining TLR4 and TLR9 agonists enhanced
the efficacy of a therapeutic vaccine against Leishmaniasis [22].
Others have found that combining a TLR3 agonist with either a
TLR2 or TLR9 agonist, or combining three agonists together can
enhance vaccines against M.tb. and HIV [17,19].
We find that the combination of GLA and CpG enhances the
production of IL-12 by macrophages ex vivo. This correlates well
with the increased magnitude of the TH1 response to vaccination
with both adjuvants. In turn this enhanced CD4+ T cell response
correlated with improved protection against aerosolized M.tb. both
in terms of a reduction in bacterial burden and decreased lung
pathology. Surprisingly this adjuvant synergy was evident in the
absence of TRIF, even though TRIF was necessary for the
adjuvant activity of GLA-SE in the absence of CpG. This suggests
that although GLA driven MyD88 signaling is not sufficient to
enhance TH1 production in the absence of TRIF, it is sufficient to
augment the MyD88 signaling outcomes driven by CpG triggering
of TLR9. Although the exact nature of this synergism in the
absence of TRIF is uncertain, it is reasonable to hypothesize that it
is dependent on enhanced IL-12 production, which we find to be
TRIF-independent when splenic macrophages are stimulated with
GLA and CpG. This latter finding expands the possible
combinations of TLR agonists that may be beneficial for enhanced
adjuvant activity.
We were surprised that the GLA and CpG synergized to
enhance IL-12 production by splenic macrophages in a TRIF-
independent fashion. A previous study found that TRIF was
necessary for enhanced IL-12 production by bone marrow derived
dendritic cells stimulated with combinations of LPS and CpG [24].
The difference in our findings and this study may stem from how
the particular cell type and preparation or possible differences
between LPS and GLA activity, although both signal via TLR4.
The discordance between our findings that TRIF is dispensable for
adjuvant synergy and previous findings that inclusion of a TRIF-
dependent agonist is necessary for adjuvant synergy may be due to
differences in model systems. Specifically we have examined the
magnitude of the polyclonal TH1 response as the measure of
adjuvant activity following repeated in vivo immunization, whereas
previous studies focused on in vitro cytokine production by
stimulated APCs and/or the ability of APCs stimulated with
combinations of TLR agonists in vitro to prime T cell responses in
vivo [16,18,38,40]. Additionally the TRIF-dependence for the
synergistic activity of multiple TLR ligands was inferred based on
the combinations of stimulants that did or did not enhance
activity, rather than testing for adjuvant cooperation in TRIF-
deficient models as we have done here.
In summary combining two distinct TLR agonists into an
adjuvanted subunit vaccine doubled the magnitude of the TH1
response and enhanced the protective efficacy. Until an effective
vaccine against TB is developed and tested clinically in efficacy
studies it will be impossible to validate correlates of protection.
Our current results provide a system to test whether the magnitude
of antigen specific CD4+ T cells is an important factor for vaccine
efficacy in the control of M.tb. either for prevention of infection or
limitation of active disease.
Supporting Information
Figure S1 Representative cytokine gating upon ex-vivo
restimulation. Splenocytes from a C57BL/6 mouse immunized
with ID93+GLA were either unstimulated (top row) or restimu-
lated with ID93 in the presence of Brefeldin A. Cells were gated as
singlets, lymphocytes, CD44+ CD4+ CD82 T cells.
(TIF)
Figure S2 ID93 adjuvanted with GLA and CpG limit
lung pathology following M.tb. infection. Mice were
immunized and challenged with a low dose of aerosolized M.tb.
four weeks later. Four weeks after infection lung sections were
stained with H&E to evaluate pathology. Data are representative
of three experiments with similar results with four mice per group.
(TIF)
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